This is a substudy (Part 2) of a larger two-part clinical trial including both observational and therapeutic (interventional) cohorts to assess the progression free survival ratio of patients treated with a targeted therapy based on genomic analysis results and recommendation by the Markey Cancer Center Molecular Tumor Board (MCC MTB).
Protocol Amendment History
10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-03-17; most recent amendment 2026-05-21.
Status change: Not Yet Recruiting → Recruiting2017-04-22